Loading…
AVLN
Avalyn Pharma Inc.
NASDAQ· Healthcare· Biotechnology
$34.69-4.98%
Key metrics
- Market cap
- $1.54B
- P/E
- —
- Forward P/E
- —
- P/B
- 3.9x
- Dividend yield
- —
- EPS
- -$2.21
- ROE
- —
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $40.17
- 52-week low
- $24.15
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
- 55
- Boston, United States
Company description provided by Yahoo Finance.